Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Psyence Biomedical Ltd. (PBM)

3.3100 -0.3000 (-8.31%)
At close: October 30 at 4:00:00 PM EDT
3.2500 -0.0600 (-1.81%)
Overnight: 8:42:52 PM EST
Chart Range Bar
Loading chart for PBM
  • Previous Close 3.6100
  • Open 3.5347
  • Bid 3.9000 x 200
  • Ask 6.4600 x 200
  • Day's Range 3.2800 - 3.6400
  • 52 Week Range 1.9200 - 122.8516
  • Volume 46,637
  • Avg. Volume 77,776
  • Market Cap (intraday) --
  • Beta (5Y Monthly) 1.73
  • PE Ratio (TTM) --
  • EPS (TTM) -12.5600
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc.

psyencebiomed.com

12

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

PBM
88.75%
S&P 500 (^GSPC)
10.73%

1-Year Return

PBM
97.29%
S&P 500 (^GSPC)
11.11%

3-Year Return

PBM
100.00%
S&P 500 (^GSPC)
81.91%

5-Year Return

PBM
100.00%
S&P 500 (^GSPC)
64.59%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -31.33%

  • Return on Equity (ttm)

    -58.62%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -6.94M

  • Diluted EPS (ttm)

    -12.5600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    7.44M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -4.96M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: